BioPharmCatalyst and BYTE51 Partner to Enable Smarter Biotech Investing Insights | PR Newswire [Video]

Comprehensive Data on Public and Private Biotech Companies Now Available to Enhance Investment Decisions

, /PRNewswire-PRWeb/ — BioPharmCatalyst, a trusted source for clinical and financial data on publicly traded biotech companies, has partnered with BYTE51, a leader in clinical trial and funding data for privately held biotech firms. This collaboration bridges the gap between public and private sector insights, empowering biotech investors and professionals with unparalleled access to critical data for more informed decision-making.

“Partnering with BYTE51 marks a significant milestone for biotech investors and professionals. We’re delivering a comprehensive solution that empowers investors to make smarter, more strategic decisions across the entire spectrum of biotech innovation.”—John Gagliano, Director of BioPharmCatalyst.

“Partnering with BYTE51 marks a significant milestone for biotech investors and professionals,” said John Gagliano, Director of BioPharmCatalyst. “By combining our expertise in public biotech data with BYTE51’s deep insights into private funding and clinical trials, we’re delivering a comprehensive …